Access versus evidence: The regulators’ dilemma

Wallach JD Ross JS Naci H . FDA’s expedited approval programs: evidentiary standards, regulatory trade-offs, and potential Improvements. Clin Trials 2018; 3: 243–245.

National Academies of Sciences Engineering Medicine. The drug development paradigm in oncology: proceedings of a workshop. Washington, DC: National Academies Press, 2017.

Prowell TM Theoret MR Pazdur R . Seamless oncology-drug development. N Engl J Med 2016; 374: 2001–2003.

Simon R . Critical review of umbrella, basket and platform designs for oncology clinical trials. Clin Pharmacol Ther 2017; 102: 934–941.

Robert C Ribas A Hamid O et al . Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma. J Clin Oncol. Epub ahead of print 28 December 2017. DOI: 101200JCO 2017756270.

US Food and Drug Administration. Guidance for industry: expedited programs for serious conditions—drugs and biologics, https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm358301.pdf (2014, accessed 5 January 2018).

European Medicines Agency. Final report on the adaptive pathways pilot, http://www.ema.europa.eu/docs/en_GB/document_library/Report/2016/08/WC500211526.pdf (2016, accessed 5 January 2018).

Blumenthal GM Kluetz PG Schneider J et al . Oncology drug approvals: evaluating endpoints and evidence in an era of breakthrough therapies. Oncologist 2017; 22: 762–767.

US Food and Drug Administration. FDA approves gemtuzumab ozogamicin for CD33-positive AML, https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm574518.htm (2017, accessed 5 January 2018).

Eichler HG Laird LG Barker R et al . From adaptive licensing to adaptive pathways: delivering a flexible life-span approach to bring new drugs to patients. Clin Pharmacol Ther 2015; 97: 234–246.

Begg CB Kim K Neaton JD . “Right to try” laws. Clin Trials 2014; 11: 519–520.